Clinical Trial Update: Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pamiparib with tamoxifen for epithelial ovarian cancer patients with biochemical recurrence during first-line PARP inhibitor maintenanc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Pamiparib (pamiparib)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Ovarian Cancer | Phase 2 | Status: UNKNOWN